JP2024133475A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024133475A5 JP2024133475A5 JP2024091743A JP2024091743A JP2024133475A5 JP 2024133475 A5 JP2024133475 A5 JP 2024133475A5 JP 2024091743 A JP2024091743 A JP 2024091743A JP 2024091743 A JP2024091743 A JP 2024091743A JP 2024133475 A5 JP2024133475 A5 JP 2024133475A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- kinase inhibitor
- composition according
- inhibitor
- kras
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862729169P | 2018-09-10 | 2018-09-10 | |
| US62/729,169 | 2018-09-10 | ||
| JP2021513254A JP7546549B2 (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
| PCT/US2019/050224 WO2020055755A1 (en) | 2018-09-10 | 2019-09-09 | Combination therapies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513254A Division JP7546549B2 (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024133475A JP2024133475A (ja) | 2024-10-02 |
| JP2024133475A5 true JP2024133475A5 (enExample) | 2025-03-14 |
Family
ID=69776771
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513254A Active JP7546549B2 (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
| JP2024091743A Pending JP2024133475A (ja) | 2018-09-10 | 2024-06-05 | 組み合わせ療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021513254A Active JP7546549B2 (ja) | 2018-09-10 | 2019-09-09 | 組み合わせ療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220040181A1 (enExample) |
| EP (2) | EP4552631A3 (enExample) |
| JP (2) | JP7546549B2 (enExample) |
| DK (1) | DK3849534T3 (enExample) |
| ES (1) | ES3017461T3 (enExample) |
| FI (1) | FI3849534T3 (enExample) |
| HR (1) | HRP20250480T1 (enExample) |
| HU (1) | HUE071715T2 (enExample) |
| LT (1) | LT3849534T (enExample) |
| PL (1) | PL3849534T3 (enExample) |
| PT (1) | PT3849534T (enExample) |
| RS (1) | RS66727B1 (enExample) |
| SI (1) | SI3849534T1 (enExample) |
| WO (1) | WO2020055755A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022500385A (ja) * | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| IL281344B2 (en) * | 2018-09-10 | 2025-09-01 | Mirati Therapeutics Inc | Combination of adagrasib and cetuximab for cancer treatment |
| CN114616232A (zh) * | 2019-09-06 | 2022-06-10 | 正大天晴药业集团南京顺欣制药有限公司 | 氮杂环庚烷并嘧啶类衍生物及其医药用途 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| KR102800341B1 (ko) | 2019-10-02 | 2025-04-23 | 톨레모 테라퓨틱스 아게 | 헤테로사이클릭 유도체, 약학 조성물 및 암의 치료 또는 개선에서 그들의 용도 |
| WO2021068898A1 (zh) * | 2019-10-10 | 2021-04-15 | 信达生物制药(苏州)有限公司 | 新颖的kras g12c蛋白抑制剂及其制备方法和用途 |
| US11654145B2 (en) | 2019-11-27 | 2023-05-23 | Turning Point Therapeutics, Inc. | Combination therapy involving diaryl macrocyclic compounds |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| TW202144349A (zh) * | 2020-04-30 | 2021-12-01 | 大陸商上海科州藥物研發有限公司 | 作為ｋｒａｓ抑制劑的雜環化合物的製備及其應用方法 |
| US11739102B2 (en) | 2020-05-13 | 2023-08-29 | Incyte Corporation | Fused pyrimidine compounds as KRAS inhibitors |
| CN113683616B (zh) * | 2020-05-18 | 2025-12-30 | 广州百霆医药科技有限公司 | Kras g12c突变蛋白抑制剂 |
| US12472179B2 (en) | 2020-06-25 | 2025-11-18 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| WO2022204112A1 (en) | 2021-03-22 | 2022-09-29 | Incyte Corporation | Imidazole and triazole kras inhibitors |
| CA3224674A1 (en) | 2021-07-07 | 2023-01-12 | Pei Gan | Tricyclic compounds as inhibitors of kras |
| CA3229855A1 (en) | 2021-08-31 | 2023-03-09 | Incyte Corporation | Naphthyridine compounds as inhibitors of kras |
| MX2024005228A (es) | 2021-11-05 | 2024-07-24 | Frontier Medicines Corp | Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras). |
| TW202535891A (zh) | 2023-10-20 | 2025-09-16 | 美商默沙東有限責任公司 | Ｋｒａｓ蛋白之小分子抑制劑 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| CN119607214B (zh) * | 2025-02-17 | 2025-06-20 | 四川大学华西医院 | Src抑制剂联合kras-g12c抑制剂用于制备治疗kras-g12c突变型肺癌的药物中的应用及药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003004492A1 (en) | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| US20040014676A1 (en) | 2001-07-09 | 2004-01-22 | Ramalinga Dharanipragada | SRC kinase inhibitors useful for treating osteoporosis |
| CN1523991A (zh) | 2001-08-10 | 2004-08-25 | ��˹��ŵ�� | 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途 |
| NZ539408A (en) | 2002-11-04 | 2007-09-28 | Astrazeneca Ab | Quinazoline derivatives as SRC tyrosine kinase inhibitors for treating solid tumours |
| US8283441B2 (en) | 2006-10-31 | 2012-10-09 | University Of Toledo | Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases |
| CA2688670A1 (en) | 2007-04-19 | 2008-10-30 | Leo Pharma A/S | Src family kinase inhibitors |
| CA2737388C (en) | 2008-09-15 | 2017-07-11 | Peter Walter | Methods and compositions for modulating ire1, src, and abl activity |
| US9090617B1 (en) | 2011-08-03 | 2015-07-28 | National Taiwan University | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
| US9216950B2 (en) | 2011-08-03 | 2015-12-22 | National Taiwan University | Agonists of Src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
| CA2944198C (en) | 2013-04-26 | 2021-11-16 | Indiana University Research & Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2) |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| JP2017528498A (ja) * | 2014-09-25 | 2017-09-28 | アラクセス ファーマ エルエルシー | Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター |
| SG11201810171SA (en) | 2016-05-18 | 2018-12-28 | Mirati Therapeutics Inc | Kras g12c inhibitors |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| PT3710439T (pt) * | 2017-11-15 | 2023-05-15 | Array Biopharma Inc | Inibidores de kras g12c |
-
2019
- 2019-09-09 PT PT198588832T patent/PT3849534T/pt unknown
- 2019-09-09 EP EP25153820.3A patent/EP4552631A3/en active Pending
- 2019-09-09 SI SI201930915T patent/SI3849534T1/sl unknown
- 2019-09-09 RS RS20250386A patent/RS66727B1/sr unknown
- 2019-09-09 ES ES19858883T patent/ES3017461T3/es active Active
- 2019-09-09 HR HRP20250480TT patent/HRP20250480T1/hr unknown
- 2019-09-09 US US17/275,175 patent/US20220040181A1/en not_active Abandoned
- 2019-09-09 DK DK19858883.2T patent/DK3849534T3/da active
- 2019-09-09 PL PL19858883.2T patent/PL3849534T3/pl unknown
- 2019-09-09 LT LTEPPCT/US2019/050224T patent/LT3849534T/lt unknown
- 2019-09-09 FI FIEP19858883.2T patent/FI3849534T3/fi active
- 2019-09-09 EP EP19858883.2A patent/EP3849534B1/en active Active
- 2019-09-09 JP JP2021513254A patent/JP7546549B2/ja active Active
- 2019-09-09 WO PCT/US2019/050224 patent/WO2020055755A1/en not_active Ceased
- 2019-09-09 HU HUE19858883A patent/HUE071715T2/hu unknown
-
2024
- 2024-06-05 JP JP2024091743A patent/JP2024133475A/ja active Pending
-
2025
- 2025-03-18 US US19/082,614 patent/US20250213579A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024133475A5 (enExample) | ||
| JP2024133474A5 (enExample) | ||
| JP2022009090A5 (enExample) | ||
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| JP2021098728A5 (enExample) | ||
| WO2004043389B1 (en) | Methods of treating cancer and related methods | |
| JPWO2021121367A5 (enExample) | ||
| JP2019508476A5 (enExample) | ||
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| WO2022218958A1 (en) | Combination comprising everolimus and amcenestrant | |
| JP2006502132A5 (enExample) | ||
| WO2022218956A1 (en) | Combination comprising ribociclib and amcenestrant | |
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
| JPWO2022182857A5 (enExample) | ||
| TWI760306B (zh) | 供治療癌症之口服投予紫杉醇及Ｐ-ｇｐ抑制劑的治療性組合 | |
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| KR20210084442A (ko) | 포도막 흑색종 치료를 위한 병용 요법 | |
| JP6370801B2 (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| JP2022177119A5 (enExample) | ||
| JP2021503448A5 (enExample) | ||
| US20230038138A1 (en) | Combination therapy for treating cancer | |
| JPWO2021260111A5 (enExample) | ||
| WO2021023291A1 (zh) | 原黄素在肺癌治疗中的应用 | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer |